THALIA THERAPEUTICS PLC

• ⚠

  Insolvency history on file

  Companies House holds prior insolvency events for this company. Detail and outcome on the official register.

1. THALIA THERAPEUTICS PLC 2026-03-17 → present
2. N4 PHARMA PLC 2017-05-02 → 2026-03-17
3. ONZIMA VENTURES PLC 2015-10-14 → 2017-05-02
4. ULTIMA NETWORKS PLC 1998-04-14 → 2015-10-14
5. MICROVITEC PUBLIC LIMITED COMPANY 1979-07-06 → 1998-04-14

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Gravita II LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“These Consolidated Financial Statements have been prepared on the basis of accounting principles applicable to a going concern. The Board has derived a mitigation plan for scenarios modelled as part of the going concern review, resulting in the issuance of shares to raise gross proceeds of £1,750,000 on 1 April 2025, providing sufficient working capital to allow the Group to meet its obligations and fund value enhancing studies for a period of at least 12 months from the signing of these Financial Statements. On this basis, the Board are satisfied with the adoption of the going concern basis in preparing the financial statements.”

Group structure

1. THALIA THERAPEUTICS PLC · parent
   1. N4 Pharma UK Limited 100% · United Kingdom · Delivery of vaccines and therapeutics
   2. Nanogenics Limited 71.21% · United Kingdom · Research and experimental development on biotechnology

Significant events

• “The Company submitted an application to the U.S. Food and Drug Administration ("FDA") in early July 2024, for the prevention of scarring following glaucoma surgery.”
• “In December 2024, the Company filed a new patent for its oral anti-inflammatory IBD product, which is in early pre-clinical development with the UK patent office.”
• “On 1 April 2025 the Company announced a placing and subscription for 437,500,000 new ordinary shares at an issue price of 0.4p to raise gross proceeds of £1,750,000.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

15

last 12 months

Capital events

2

last 24 months

Officers appointed

3

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +272.9%

  £1,953 → £7,282

• Cash

  -39.1%

  £1,027,112 → £625,972

• Net assets

  -45.4%

  £1,193,641 → £651,402

• Employees

  -20%

  5 → 4

• Profit before tax

  +14.3%

  -£1,424,594 → -£1,221,101

• Wages

  -3.1%

  £214,000 → £207,467

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers